In pancreatic ductal adenocarcinoma, NBL1 inhibits tumor growth by antagonizing bone morphogenetic protein 2/4 (BMP2/4) signaling and suppressing EMT, whereas in lung adenocarcinoma, NBL1 acts as a transcriptional target of miR-1301-3p to suppress metastasis. Here, NBL1 is linked to pancreatic ductal adenocarcinoma.